Evaxion A/S has out-licensed its vaccine candidate EVX-B3 to MSD under an agreement that secures an initial payment of $7.5 million. The partnership will allow MSD to manage all further development costs and also entitles Evaxion to future milestone payments and royalties.
Company Information
Company
Evaxion A/S
Location
5f Doktor Neergaards Vej
Copenhagen, Capital Region Of Denmark, Denmark
About
Evaxion A/S is a clinical-stage TechBio company based in Copenhagen, Denmark. It specializes in developing AI-Immunology™ powered vaccines. The company focuses on addressing serious global medical issues through innovative vaccine candidates. Evaxion aims to harness the power of artificial intelligence to uncover novel vaccine targets.
Predictive Intelligence
Strategic
ML-powered predictions for Evaxion A/S's next move